These events were generally mild to moderate in severity and included: Nausea often accompanying changes in bowel habits, particularly after dose escalation Diarrhoea loose or watery stools, sometimes with urgency Vomiting less common but reported, especially at higher doses Constipation occurring in some individuals, reflecting the variable effect on gut motility Abdominal discomfort or bloating a sensation of fullness or cramping Flatulence increased wind, which can accompany altered digestion Gastrointestinal adverse events were the most common reason for discontinuation in the Phase 2 trial, occurring in approximately 510% of participants depending on dose group
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Inoltre, riduce la preferenza per gli alimenti ad alto contenuto di grassi
DNA damage following UVB exposure induces MMP-1 production by increasing MMP-1 gene expression in keratinocytes (31,54,55)
Without Clinical Oversight GLP-1 medications carry real risks that HumeCare's own safety materials disclose in detail - a boxed warning regarding thyroid tumors, contraindications for certain personal and family medical histories, and interactions with other medications including insulin, sulfonylureas, and oral contraceptives
patients met the studys full efficacy estimand criteria, which corresponded to an average weight loss of 15.67 % over a period of 12 months
